A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation

NCT ID: NCT05049850

Last Updated: 2025-10-21

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 3 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-12-16
• Study Completion Date: 2024-05-08

Brief Summary

The purpose of this study is to assess whether imlifidase in combination with bortezomib, belatacept, rituximab and IVIg can suppress donor specific antibodies (DSA) and the occurrence of antibody-mediated rejection (AMR) in highly sensitized patients with chronic kidney disease with a positive crossmatch towards their living donor during a period of 3 months from transplantation.

Detailed Description

Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly specific for IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG. Clinical studies with imlifidase have demonstrated that the treatment enables transplantation in patients otherwise highly unlikely to be transplanted, by converting a positive crossmatch to a negative.

However, as with other desensitization methods, DSA tend to reappear within weeks after treatment and transplantation, which may cause AMR and increased risk of graft loss. In this study, treatment with imlifidase in combination with approved drugs that prevent or suppress DSA rebound by targeting antibody-producing plasma-cells and their B-cell precursors is suggested. These drugs include (i) bortezomib, a proteasome inhibitor which has activity against mature plasma cells, the source of DSA, (ii) belatacept, a fusion protein which is crucial in blocking T-cell co-stimulation and which is effective in reducing de novo DSA generation in humans, (iii) rituximab, an anti-CD20 monoclonal antibody that targets B-cells and which is an immunomodulatory agent, and (iv) intravenous immunoglobulin (IVIg) which is commonly used in desensitization regimens and for the treatment of AMR.

After being informed about the study and potential risks, all patients giving written informed consent will undergo a 2-week screening period to determine eligibility for study entry. Patients who meet the eligibility requirements will then start treatment with belatacept and bortezomib about 3 weeks prior to the imlifidase infusion and transplantation. Rituximab will be initiated 8 days after transplantation and IVIg 10 days after transplantation. Induction and maintenance immunosuppression will also be administered. The patients will be hospitalized for approximately 2 weeks following transplantation and after that 9 follow-up visits to the clinic will take place up to 6 months after transplantation.

Conditions

Kidney Transplantation in Highly Sensitized Patients

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Imlifidase

Imlifidase is administered intravenously as one dose of 0.25 mg/kg over 15 minutes within the 24-hour period prior to transplantation. (A second dose may be given if the crossmatch test at 4 hours after the first dose remains positive.)

Group Type: EXPERIMENTAL

Imlifidase

Intervention Type: DRUG

Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly specific for IgG.

Interventions

Imlifidase

Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly specific for IgG.

Intervention Type: DRUG

Other Intervention Names

IdeS, HMED-IdeS

Eligibility Criteria

Inclusion Criteria

• Signed Informed Consent obtained before any trial-related procedures
• Male or female age 18 to 70 years at the time of screening
• Highly sensitized patients registered on the UNOS waiting list for kidney transplantation, with either of the following:

• cPRA ≥ 99.9%
• cPRA ≥ 98% and have been in kidney paired donation or kidney paired exchange programs for at least 1 year
• A positive crossmatch towards a living donor
• Willingness and ability to comply with the protocol

Exclusion Criteria

• Previous treatment with imlifidase
• Previous high dose IVIg treatment (2 g/kg) within 28 days prior to imlifidase treatment
• Breast-feeding or pregnancy
• Women of child-bearing potential not willing or able to practice FDA-approved forms of contraception. Two medically acceptable methods of highly effective contraception must be used for the duration of the study (e.g. oral, transdermal, intravaginal, injectable or implantable contraceptive; intrauterine device; intrauterine hormone-releasing system; vasectomized partner; bilateral tubal occlusion; or double-barrier method). For a woman to be considered postmenopausal this ascertainment must be made according to medical records and clinical history and may be aided by measurement of elevated postmenopausal serum gonadotropin levels (FSH).
• ABO blood group incompatible transplantations (A2 and A2B kidneys will not be accepted for B recipients)
• Positive serology for HIV
• Clinical signs of HBV, HCV, CMV, or EBV infection
• EBV seronegative or with unknown EBV serostatus
• Positive SARS-CoV-2 tests at any time point from screening to transplantation
• Active tuberculosis
• Ongoing serious infections as judged by the investigator
• Severe other conditions requiring treatment and close monitoring e.g. cardiac failure ≥ grade 4 (New York Heart Association), unstable coronary disease or oxygen dependent respiratory disease
• A history of a proven hypercoagulable condition
• Present, or history of, thrombotic thrombocytopenic purpura (TTP) or known familial history of TTP
• Intake of investigational drugs (other than imlifidase) within 5 half-lives
• Contemporaneous participation in a medical device study
• Known allergy/sensitivity (except local reactions) to imlifidase or to any drug (or the excipients) specified in the protocol
• Known mental incapacity or language barriers precluding adequate understanding of the Informed Consent information and the trial activities
• Inability by the judgement of the investigator to participate in the trial for any other reason

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hansa Biopharma AB

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Operations

Role: STUDY_DIRECTOR

Hansa Biopharma AB

Locations

NYU Langone Health Transplant Institute

New York, New York, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

18-HMedIdeS-16

Identifier Type: -

Identifier Source: org_study_id